Stoke Therapeutics completes dosing in first two cohorts of Phase 1 OSPREY trial for STK-002 in optic atrophy

• Stoke Therapeutics presented new preclinical findings for STK-002 in autosomal dominant optic atrophy at AAO 2026.
• Data supported a disease-modifying approach aimed at restoring OPA1 protein levels to slow or alter progressive vision loss.
• Phase 1 OSPREY dose escalation continued, with dosing completed in the first two cohorts; third cohort dosing targeted by end-2026.
• Initial safety and early efficacy readouts from higher-dose cohorts are expected in H1 2027, to guide further development plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610120800BIZWIRE_USPR_____20261012_BW027670) on October 12, 2026, and is solely responsible for the information contained therein.